Korman, N., Papp, K., Bagel, J. ., Foley, P., Morita, A., Banerjee, S., Colston, E., Wang, T., Throup, J. and Thaci, D. (2021) “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials”, SKIN The Journal of Cutaneous Medicine, 5(6), p. s39. doi: 10.25251/skin.5.supp.39.